Insights › Makamashi da yanayi › November 15, 2026
Makamashi da yanayi · Ayyukan da ake kan yi da ci gaba

IDEAYA Biosciences Ta Sanar da Zaɓin 'Dan Takarar Ci gaba na IDE101, Mai Hana Cutar da ta Farko a Irinsa wanda ke Nufin Rashin CDKN2A a Cikin Tumour Mai Ƙarfi

PR Newswire (Health) An wallafa: Trial

'Dan takarar ci gaba ya nuna aikin gwaji na farko mai ban sha'awa a cikin samfuran tumour marasa lafiya na CDKN2A azaman magani ɗaya kuma a haɗe tare da masu hana RAS da MTAP, gami da mai hana PRMT5 na Mataki na 1 na IDEAYA wanda yake mallakar ta IDE892 Rashin CDKN2A shine asarar mai hana tumour gama gari...

Asalin tushe
Karanta tushen — prnewswire.com ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Makamashi da yanayi

Duba komai a cikin Makamashi da yanayi →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.